Nuventra is proud to announce its participation at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and Exposition on March 21 – 24, 2018 in Orlando, FL. Nuventra’s scientists will participate in two oral presentations and two poster sessions. The team will also exhibit during the conference at Booth #515.
Virginia (Ginny) Schmith, Ph.D., FCP will speak twice during this year’s conference. The first presentation is titled, “Collaboration Across Fields to Minimize Placebo Response and Maximize the Potential for Positive Phase III Outcomes,” and will be held on Thursday, March 22, at 10:30 a.m. The second is titled, “Evaluation of RBP-6000 Effects on QT Interval During Treatment for Opioid Use Disorder,” and will be held on March 23, at 1:45 p.m.
Nuventra’s first poster presentation is also titled, “Evaluation of RBP-6000 Effects on QT Interval During Treatment for Opioid Use Disorder,” written and presented by Ginny Schmith, Laura Curd, Lauren Lohmer, Celinne M. Laffont, Anne Andorn, and Malcolm A. Young. Nuventra’s second poster presentation is titled, “Pharmacokinetics of Mazindol and its Hydrolysis Metabolite after Administration of a Single Dose of Mazindol CR in Healthy Subjects,” written and presented by Scott J. Brantley, Betty Hussey, Rex Williams, Jessica Higgins, and Ginny Schmith.
David Y. Mitchell, Ph.D., Nuventra’s Chief Scientific Officer, will serve as ASCPT’s President-Elect starting in March 2018. Dr. Mitchell’s term as President begins in March 2019. In addition, Ginny Schmith, Ph.D., FCP, Vice President of Clinical Pharmacology and Pharmacometrics, will continue her 3-year term on the board of directors this year.
Nuventra is a proud Bronze Level Sponsor for the event. “We are glad to continue to be a part of this great organization,” said President and CEO of Nuventra, Geoffrey Banks, Ph.D. “Nuventra takes pride in attracting some of the industry’s leading experts, such as Dr. Mitchell and Dr. Schmith, who support the ASCPT community, which strives towards the development of safe and effective drugs,” continued Dr. Banks.